GAGhasem Ahangari

Ghasem Ahangari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ghasem Ahangari has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Arezoo Campbell

    Department of Pharmaceutical Sciences Western University of Health Sciences Pomona California USA

    4 shared publications
  • Fatemeh Abedini

    Department of Medical Genetics, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran

    3 shared publications
  • Hamid Reza Ahmadkhaniha

    Tehran Psychiatric Institute, Iran University of Medical Sciences, Tehran; World Health Organization Collaborating Center for Mental Health, Tehran, Iran

    3 shared publications
  • Majid Pornour

    Department of Photo Healing and Regeneration, Medical Laser Research Center, Yara Institute, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran

    3 shared publications
  • Naghmeh Gholipour

    Department of Medical Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran

    3 shared publications
  • Omolbanin Amjadi

    Department of Medical Genetics, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran

    3 shared publications

Latest Publications

  • Repositioning serotonergic antagonists as therapeutic agents in gastric cancer: induction of apoptosis, inhibition of cell migration, and cell cycle arrest in AGS cells

    by Fatemeh Abedini, Parisa Amjadi, Ghasem Ahangari

    Drug repurposing in oncology can reduce the time and cost of new drug development. Studies suggest that depression influences tumor progression, and some antidepressants exhibit anti-tumor effects. This study evaluated the effects of serotonergic antagonists—tropisetron, imipramine, ketanserin, and cyproheptadine—on AGS gastric cancer cells. The half-maximal inhibitory concentration (IC50) values of drugs were determined after 48 h in AGS cells using the MTT assay. Cell cycle distribution and apoptosis were evaluated by flow cytometry. Morphological changes were observed by Acridine Orange/Ethidium Bromide staining. The wound-healing assay was used to assess the effects of the drugs on cell migration. Real-time PCR was used to measure the expression of 5-hydroxytryptamine (5-HT) receptors (5-HT2A, 5-HT2B, 5-HT3A), serotonin transporter (SLC6A4/SERT), apoptosis-related genes (Bcl-2, Bax), and proliferating cell nuclear antigen (PCNA). All drugs significantly inhibited the growth of AGS cell in vitro. All four drugs induced apoptosis and inhibited cell migration with varying efficacies. Imipramine induced G1/S phase arrest, whereas tropisetron, ketanserin, and cyproheptadine increased the sub-G1 cell population. Gene expression analysis revealed decreased Bcl-2 and PCNA levels and increased Bax expression.These findings suggest the potential of tropisetron, imipramine, ketanserin, and cyproheptadine as repurposed therapeutic agents for gastric cancer.


  • Open Access

    Impact of pesticide diazinon on gastric cancer cell lines and the alteration of cholinergic and serotonergic pathway genes affecting cell proliferation

    by Shadi Ghaemi, Fatemeh Abedini, Amir Mousavi, Ghasem Ahangari

    Diazinon (DZN) is an organophosphorus (OP) pesticide implicated in carcinogenesis. Its primary mechanism of action is inhibition of acetylcholinesterase (AChE). We evaluated the impact of low-dose DZN on two gastric cancer (GC) cell lines (AGS, MKN-45), focusing on cholinergic and serotonergic signaling. Proliferation-stimulatory concentrations were identified by MTT assay (0.1 µM for AGS, 0.01 µM for MKN-45). Scratch assays demonstrated enhanced migration at low doses but suppression at high dose. AO/EB staining confirmed reduced viability with increased apoptosis at high dose. Cell cycle analysis further revealed S-phase accumulation. qRT-PCR demonstrated upregulation of CHRM3, SLC18A3, HTR2A/B, SLC6A4, BCL2 and PCNA, with concomitant downregulation of ACHE, MAOA and BAX in both lines; HTR3A and HTR7 were selectively elevated in AGS cells. Complementary in silico analysis of gastric tumor RNA-seq data (GSE113255) confirmed differential expression of neurotransmission-related genes and enrichment of cholinergic/serotonergic pathways. Collectively, these data indicate that submicromolar DZN promotes proliferation and suppresses apoptosis of GC cells by perturbing neuronal signaling networks. Our findings provide novel evidence linking environmental OP exposure to dysregulated neurotransmitter pathways in gastric carcinogenesis and highlight neuronal signaling components as potential therapeutic or preventive targets.


  • Repurposing serotonergic drugs for gastric cancer: induction of apoptosis in vitro

    by Fatemeh Abedini, Omolbanin Amjadi, Ghasem Ahangari

    Gastric cancer is a highly heterogeneous and aggressive disease with limited treatment options, necessitating innovative therapeutic strategies. Drug repurposing, a cost-effective approach, offers opportunities to identify new applications for existing medications. This study systematically investigated the apoptotic effects of serotonergic drugs on MKN-45 gastric cancer cells, providing a novel perspective on serotonin signaling in cancer therapy. MKN-45 cells were treated with concentrations of Tropisetron, Imipramine, Ketanserin, Citalopram, and Cyproheptadine. The IC50 values were determined using an MTT assay, while acridine orange/ethidium bromide staining and Annexin V/PI flow cytometry assessed apoptotic activity. Gene expression related to serotonin receptors (HTR2A, HTR2B, HTR3A), Serotonin transporter (SLC6A4), apoptosis (Bcl-2, Bax), and proliferation (PCNA) was evaluated via real-time PCR. Tropisetron, Imipramine, Ketanserin, and Cyproheptadine demonstrated statistically significant apoptotic induction compared to untreated cells. These treatments significantly reduced anti-apoptotic Bcl-2 and PCNA, proliferation marker, expression, while pro-apoptotic Bax expression was markedly elevated (p < 0.05). This study highlights the potential of Tropisetron, Imipramine, Ketanserin, and Cyproheptadine as repurposed drugs for gastric cancer therapy, with Tropisetron and Imipramine showing particularly promising apoptotic effects. These findings pave the way for further preclinical and clinical investigations, offering a foundation for personalized therapeutic strategies in gastric cancer management.


  • Revealing New Prospects: Antipsychotic Drugs Induces Anti-tumor Effects against Gastric Cancer through Inducing Apoptosis

    by Omolbanin Amjadi, Akbar Hedayatizadeh-Omran, Ehsan Zaboli, Ghasem Janbabaei, Sergio A Lira, Ghasem Ahangari

    Background and Objective: Globally, Gastric Cancer (GC) ranks as the fifth leading cause of cancer-related deaths. GC is a multifaceted malignancy with diverse etiologies; how-ever, understanding the shared molecular mechanisms can aid in discovering novel targeted therapies for GC. This study has employed a drug repositioning approach to explore new drug candidates for treating GC. Methods: The human GC cell lines AGS, MKN-45, and KATO-III were treated with different concentrations of dopamine, cabergoline, thioridazine, and entacapone to determine effective doses and IC50 values. In vitro, cytotoxic activity on cancer cell lines was screened based on dose/time using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as-say. Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) was used to measure the mRNA expression of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), and Proliferating Cell Nuclear Antigen (PCNA) in each group. The percentage of apoptotic cells was evaluated using Annexin V/PI staining. Results: Dopamine, cabergoline, thioridazine, and entacapone elicited cytotoxic effects on AGS and KATO-III cells in a dose-dependent manner and elevated the percentage of Annexin V-positive cells, suggesting the occurrence of apoptosis. The expression of Bcl-2 and PCNA was significantly decreased, whereas the expression of Bax was considerably increased in the AGS and KATO-III cells compared to that in the blank group (p < 0.05); however, no similar effect was observed in MKN-45 cells. Conclusion: Through in vitro experiments, this study provides evidence that the antipsychotic drugs cabergoline, dopamine, thioridazine, and entacapone can inhibit gastric cancer growth in AGS and KATO-III cells. These findings suggest that these drugs could be repurposed as novel therapeutic agents for the treatment of gastric cancer.


  • Exploring neuroadaptive cellular pathways in chronic morphine exposure: An in‐vitro analysis of cabergoline and Mdivi‐1 co‐treatment effects on the autophagy–apoptosis axis

    by Mina Makvand, Seyed Davood Mirtorabi, Arezoo Campbell, Alireza Zali, Ghasem Ahangari

    The complex impacts of prolonged morphine exposure continue to be a significant focus in the expanding area of addiction studies. This research investigates the effectiveness of a combined treatment using Cabergoline and Mdivi‐1 to counteract the neuroadaptive changes caused by in vitro morphine treatment. The impact of Methadone, Cabergoline, and a combination of Cabergoline and Mdivi‐1 on the cellular and molecular responses associated with Morphine‐induced changes was studied in human Neuroblastoma (SK‐N‐MC) and Glioblastoma (U87‐MG) cell lines that were exposed to prolong Morphine treatment. Cabergoline and Mdivi‐1 combined treatment effectively influenced the molecular alterations associated with neuroadaptation in chronic morphine‐exposed neural cells. This combination therapy normalized autophagy and reduced oxidative stress by enhancing total‐antioxidant capacity, mitigating apoptosis, restoring BDNF expression, and balancing apoptotic elements. Our research outlines morphine's dual role in modulating mitochondrial dynamics via the dysregulation of the autophagy–apoptosis axis. This emphasizes the significant involvement of DRP1 activity in neurological adaptation processes, as well as disturbances in the dopaminergic pathway during in vitro chronic exposure to morphine in neural cells. This study proposes a novel approach by recommending the potential effectiveness of combining Cabergoline and Mdivi‐1 to modulate the neuroadaptations caused by morphine. Additionally, we identified BDNF and PCNA in neural cells as potential neuroprotective markers for assessing the effectiveness of drugs against opioid toxicity, emphasizing the need for further validation. The study uncovers diverse effects observed in pretreated morphine glioblastoma cells under treatment with Cabergoline and methadone. This highlights the potential for new treatments in the DRD2 pathway and underscores the importance of investigating the interplay between autophagy and apoptosis to advance research in managing cancer‐related pain. The study necessitates an in‐depth investigation into the relationship between autophagy and apoptosis, with a specific emphasis on protein interactions and the dynamics of cell signaling.


  • Open Access

    Predictive Factors for Methadone Maintenance Treatment Compliance: Exploring Resistance and Tolerance in Heroin Addiction

    by Mina Makvand, Seyed Davood Mirtorabi, Arezoo Campbell, Ghasem Ahangari

    Background: Methadone maintenance treatment (MMT) has been a cornerstone in heroin addiction management. However, its efficacy varies among individuals. The complex interplay of genetic backgrounds and demographic data could influence the response to MMT in heroin addiction. No previous adoption study has aimed to merge these findings into a potential pre-treatment screening tool. Objectives: This study aimed to investigate the combined influence of dopamine and opioid receptors and receptor endocytosis machinery genes, individual genetic backgrounds, and demographic data on the response to MMT in patients with heroin addiction. Methods: We enrolled 80 heroin addicts receiving MMT for 3 months alongside 80 healthy individuals in a comparative study. The approach utilized multinomial, linear, and binary logistic regression analyses to investigate the interplay of genetic factors (DRD1-5, opioid receptors [µ1, δ1, and κ1], DNM1L, RAB22A, and COMT), demographic independent variables, including, family history, heroin duration, age onset, heroin dose, and methadone dose, and clinical markers Subjective Opiate Withdrawal Scale (SOWS) with compliance with MMT protocols. Results: Results revealed that a positive family history and a higher level of heroin dose significantly predicted poor compliance to MMT. Additionally, the patients with lower expression levels of DRD2 and higher expression levels of DNM1L and COMT genes were at higher risk for poor compliance with the treatment. Conclusions: By utilizing a comprehensive dataset of gene expression profiles and demographic and clinical parameters, this study developed a regression model predicting resistance or response to methadone. This innovative approach seeks to bridge the gap between pharmacogenomics and clinical practice and offer a potential pre-treatment screening tool for personalized MMT strategies in opioid addiction management. The obtained findings hold intriguing promise for future research, potentially unlocking deeper insights into the underlying risk factors of addiction.


  • Dopamine receptors gene overexpression in the microenvironment of invasive gastric cancer and its potential implications

    by Omolbanin Amjadi, Akbar Hedayatizadeh-Omran, Ehsan Zaboli, Mohammad Mehdi Ghaffari-Hamedani, Ghasem Janbabaei, Ghasem Ahangari

    Background Gastric cancer (GC) is the fifth most common cancer worldwide and the most commonly diagnosed cancer in Iran. The nervous system provides proximity to tumor cells by releasing neurotransmitters such as dopamine and presenting them to the corresponding receptor-bearing tumors. While nerve fibers infiltrate the tumor microenvironment, little is known about the expression levels of dopamine (DA), dopamine receptors (DRs), and catechol-O-methyltransferase (COMT) in GC patients. Methods DRs and COMT expression were analyzed in 45 peripheral blood mononuclear cells (PBMCs) and 20 paired tumor and adjacent tissue of GC patients by quantitative polymerase chain reaction. DA was measured in plasma specimens using enzyme-linked immunosorbent assay. Protein-protein interaction analysis was carried out to identify GC-related hub genes. Results Increased expression of DRD1-DRD3 was found in tumor specimens compared with adjacent non-cancerous specimens (P < 0.05). A positive correlation was found between DRD1 and DRD3 expression (P = 0.009); DRD2 and DRD3 expression (P = 0.04). Plasma levels of dopamine were significantly lower in patients (1298 pg/ml) than in controls (4651 pg/ml). DRD1–DRD4 and COMT were up-regulated in PBMCs of patients compared with controls (P < 0.0001). Bioinformatic analyses showed 30 hub genes associated with Protein kinase A and extracellular signal-regulated kinase signaling pathways. Conclusions The findings indicated dysregulation of DRs and COMT mRNA expression in GC and suggest that the brain- gastrointestinal axis may mediate gastric cancer development. Network analysis revealed that combination treatments could be considered for optimizing and improving the precision treatment of GC.